Regulatory Approval Pathway for Biomaterials

In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we discuss what the implementation of a regulatory approval pathway for biomaterials would mean for medical device manufacturers, patients, and the healthcare industry. While such a pathway doesn’t currently exist, the potential advantages are explored. Further, the competitive advantage such a pathway could offer to materials manufacturers and suppliers is presented. Specifically, the following questions and topics are addressed in this discussion:
 

• Currently, can biomaterials be approved by FDA?
• Drugs are approved, and a drug is sort of a “biomaterial” so shouldn’t biomaterials be approved?
• If we haven't had a biomaterial approval pathway thus far, why do we need one now?
• How many companies developing new medical devices vs. how many companies developing new biomaterials?
• What are device manufacturers more likely to do: develop a new device using an existing material vs. developing a new device using a new material? Which would you choose?
• Would there be advantages to having a biomaterials approval pathway?
• Would there be disadvantages to having a biomaterials approval pathway?
• What is the likelihood of this happening?

Listen to the podcast streaming via the player or get the podcast on the Medtech Matters channel via your preferred vendor of podcasts, such as Apple Podcasts (iTunes) or Spotify.
 
Once you’ve had a chance to listen to the podcast, if you have any questions or comments you’d like us to discuss or share with other Mike on Medtech listeners about this topic or any other topic we’ve addressed, or you have a suggestion for a future topic for us to cover, email me at [email protected] and we’ll try to respond in an upcoming Mike on Medtech podcast.

Send us a text

For more medtech news and information, visit https://www.mpomag.com.